For the first time in its 16-year history, Deloitte’s annual report on pharma R&D returns sees obesity replace cancer as the largest driver.

After abandoning an IPO bid last year, Odyssey is trying again, emboldened by recent big-value listings that suggest 2026 could be a bumper year.

The FDA has narrowed its search for a new leader of its Center for Biologics Evaluation and Research to three to four final candidates, according

The Supreme Court restored mail ordering of mifepristone reversing a federal appeals court’s stay. The decision Monday came after makers of the pill asked for

Celcuity’s breast cancer drug wins again: The company said two regimens with its experimental drug gedatolisib succeeded in PIK3CA mutant patients as part of its